Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
Aurélie Courtin, Nicola G. Wallis(Biota Pharmaceuticals (United States))
Cited by 28
Related Papers
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells
|Cancer Research|2016|91
The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
|Molecular Cancer Therapeutics|2012|59